Biological Markers in Epidemiology PDF Download

Author: Barbara S. Hulka
Publisher: Oxford University Press, USA
ISBN: 9780195059847
Category : Medical
Languages : en
Pages : 236

View

Book Description
This comprehensive volume provides a state-of-the-art perspective on methodological considerations in the use of biological markers in epidemiologic studies. The text discusses the use of biological markers for evaluation, biological responses, biologically effective dosage, internal dose, and susceptibility; methodological issues such as classification, sensitivity, stability, variability, and confounding variables are thoroughly examined. The characteristics of several specific classes of markers, such as sister-chromatid-exchange, protein and DNA adducts, micronuclei, urine mutagenicity assays, chromosome aberrations and oncogenes are described. Markers of susceptibility such as N-acetyltransferase are also discussed. Effective sample collection procedures, sensitive and specific assays for detection of the marker in the medium of choice are given careful consideration, as are the methodological issues applicable to epidemiologic studies.

Author: Paul A. Schulte
Publisher: Academic Press
ISBN: 0323138578
Category : Science
Languages : en
Pages : 588

View

Book Description
This book will serve as a primer for both laboratory and field scientists who are shaping the emerging field of molecular epidemiology. Molecular epidemiology utilizes the same paradigm as traditional epidemiology but uses biological markers to identify exposure, disease or susceptibility. Schulte and Perera present the epidemiologic methods pertinent to biological markers. The book is also designed to enumerate the considerations necessary for valid field research and provide a resource on the salient and subtle features of biological indicators.

Author: National Research Council
Publisher: National Academies Press
ISBN: 0309052289
Category : Science
Languages : en
Pages : 322

View

Book Description
Diseases of the kidney, bladder, and prostate exact an enormous human and economic toll on the population of the United States. This book examines prevention of these diseases through the development of reliable markers of susceptibility, exposure, and effect and the promise that new technologies in molecular biology and sophisticated understanding of metabolic pathways, along with classical approaches to the study of nephrotoxicants and carcinogens, can be developed and prevention of the diseases achieved. The specific recommendations included in this book complement those made in the previous three volumes on biomarkers, Biologic Markers in Reproductive Toxicology (1989), Biologic Markers in Pulmonary Toxicology (1989), and Biologic Markers in Immunotoxicology (1991).

Author: P. Toniolo
Publisher:
ISBN:
Category : Medical
Languages : en
Pages : 340

View

Book Description
This publication originates from an international workshop which addresses a range of methodological issues underlying the use of biological markers of exposure, biological effects and individual susceptibility in cancer epidemiology. It includes a report of the workshop, with a general discussion and recommendation on epidemiology. a series of peer-reviewed authored contributors provide a more personal view on the most important aspects by key researchers.

Author: National Research Council
Publisher: National Academies Press
ISBN: 0309176832
Category : Science
Languages : en
Pages : 150

View

Book Description
Growing public concern about releases of radiation into the environment has focused attention on the measurement of exposure of people living near nuclear weapons production facilities or in areas affected by accidental releases of radiation. Radiation-Dose Reconstruction for Epidemiologic Uses responds to the need for criteria for dose reconstruction studies, particularly if the doses are to be useful in epidemiology. This book provides specific and practical recommendations for whether, when, and how studies should be conducted, with an emphasis on public participation. Based on the expertise of scientists involved in dozens of dose reconstruction projects, this volume: Provides an overview of the basic requirements and technical aspects of dose reconstruction. Presents lessons to be learned from dose reconstructions after Chernobyl, Three Mile Island, and elsewhere. Explores the potential benefits and limitations of biological markers. Discusses how to establish the "source term"â€"that is, to determine what was released. Explores methods for identifying the environmental pathways by which radiation reaches the body. Offers details on three major categories of dose assessment.

Author: National Research Council
Publisher: National Academies Press
ISBN: 0309044960
Category : Science
Languages : en
Pages : 297

View

Book Description
The amount of hazardous waste in the United States has been estimated at 275 million metric tons in licensed sites alone. Is the health of Americans at risk from exposure to this toxic material? This volume, the first of several on environmental epidemiology, reviews the available evidence and makes recommendations for filling gaps in data and improving health assessments. The book explores: Whether researchers can infer health hazards from available data. The results of substantial state and federal programs on hazardous waste dangers. The book presents the results of studies of hazardous wastes in the air, water, soil, and food and examines the potential of biological markers in health risk assessment. The data and recommendations in this volume will be of immediate use to toxicologists, environmental health professionals, epidemiologists, and other biologists.

Author: Jean-Paul Goulet
Publisher: Springer
ISBN: 3662539942
Category : Medical
Languages : en
Pages : 155

View

Book Description
This book provides up-to-date information on all aspects of orofacial pain biomarkers. It opens by presenting background information on clinical phenotypes and the neurobiological substrates underlying chronic orofacial pain and by explaining the potential role of biomarkers in the diagnosis, prognostic evaluation, and treatment of orofacial pain. The main section of the book examines the contribution of human and animal studies to the field of biomarkers for orofacial pain and discusses biomarkers for masticatory muscle pain, temporomandibular joint pain, neuropathic face pain, and autonomic nervous system involvement in trigeminal facial pain. The potential impacts of the immune system on orofacial pain biomarkers and candidate gene phenotypes with possible links to chronic orofacial pain conditions are also addressed, and differences and similarities between saliva and serum biomarkers for pain are explained as well. The final section covers research-related issues in assessment methods and statistical analyses used in evaluating biomarkers, identifies future challenges and suggests new directions in the field.

Author: Chris Wild
Publisher: John Wiley & Sons
ISBN: 1119965616
Category : Science
Languages : en
Pages : 435

View

Book Description
"I think this is an excellent book–I recommend it to anyone involved in molecular epidemiology... The 26 chapters are written by topic specialists, in an explanatory, east to read style." –BTS Newsletter, Summer 2009 "This text provides an accessible and useful handbook for the epidemiologist who wants to survey the field, to become better informed, to look at recent developments and get some background on these or simply to appreciate further the relatively rapid changes in informatic and analytical technologies which increasingly will serve and underpin future epidemiological studies. One of the strengths in this book is the extensive array of practical illustrative examples, and it would also in my opinion have useful potential as a teaching text." –American Journal of Human Biology, March 2009 With the sequencing of the human genome and the mapping of millions of single nucleotide polymorphisms, epidemiology has moved into the molecular domain. Scientists can now use molecular markers to track disease-associated genes in populations, enabling them to study complex chronic diseases that might result from the weak interactions of many genes with the environment. Use of these laboratory generated biomarker data and an understanding of disease mechanisms are increasingly important in elucidating disease aetiology. Molecular Epidemiology of Disease crosses the disciplinary boundaries between laboratory scientists, epidemiologists, clinical researchers and biostatisticians and is accessible to all these relevant research communities in focusing on practical issues of application, rather than reviews of current areas of research. Covers categories of biomarkers of exposure, susceptibility and disease Includes chapters on novel technologies: genomics, transcriptomics, proteomics and metabonomics, which are increasingly finding application in population studies Emphasizes new statistical and bioinformatics approaches necessitated by the large data sets generated using these new methodologies Demonstrates the potential applications of laboratory techniques in tackling epidemiological problems while considering their limitations, including the sources of uncertainty and inaccuracy Discusses issues such as reliability (compared to traditional epidemiological methods) and the timing of exposure Explores practical elements of conducting population studies, including biological repositories and ethics Molecular Epidemiology of Disease provides an easy-to-use, clearly presented handbook that allows epidemiologists to understand the specifics of research involving biomarkers, and laboratory scientists to understand the main issues of epidemiological study design and analysis. It also provides a useful tool for courses on molecular epidemiology, using many examples from population studies to illustrate key concepts and principles.

Author: Michael R. Bleavins
Publisher: John Wiley & Sons
ISBN: 1118210425
Category : Medical
Languages : en
Pages : 559

View

Book Description
Discover how biomarkers can boost the success rate of drug development efforts As pharmaceutical companies struggle to improve the success rate and cost-effectiveness of the drug development process, biomarkers have emerged as a valuable tool. This book synthesizes and reviews the latest efforts to identify, develop, and integrate biomarkers as a key strategy in translational medicine and the drug development process. Filled with case studies, the book demonstrates how biomarkers can improve drug development timelines, lower costs, facilitate better compound selection, reduce late-stage attrition, and open the door to personalized medicine. Biomarkers in Drug Development is divided into eight parts: Part One offers an overview of biomarkers and their role in drug development. Part Two highlights important technologies to help researchers identify new biomarkers. Part Three examines the characterization and validation process for both drugs and diagnostics, and provides practical advice on appropriate statistical methods to ensure that biomarkers fulfill their intended purpose. Parts Four through Six examine the application of biomarkers in discovery, preclinical safety assessment, clinical trials, and translational medicine. Part Seven focuses on lessons learned and the practical aspects of implementing biomarkers in drug development programs. Part Eight explores future trends and issues, including data integration, personalized medicine, and ethical concerns. Each of the thirty-eight chapters was contributed by one or more leading experts, including scientists from biotechnology and pharmaceutical firms, academia, and the U.S. Food and Drug Administration. Their contributions offer pharmaceutical and clinical researchers the most up-to-date understanding of the strategies used for and applications of biomarkers in drug development.

Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309157277
Category : Medical
Languages : en
Pages : 335

View

Book Description
Many people naturally assume that the claims made for foods and nutritional supplements have the same degree of scientific grounding as those for medication, but that is not always the case. The IOM recommends that the FDA adopt a consistent scientific framework for biomarker evaluation in order to achieve a rigorous and transparent process.